

## Novavax Investor Relations

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax' coronavirus vaccine candidate, on Wednesday, May 13, 2020 as part of the World Vaccine Congress' COVID-19 webinar series. Dr. Glenn joins a distinguished group of global public health, epidemiology, regulatory and industry leaders in sharing expertise and information related to the SARS-Cov-2 virus, as well as ongoing efforts to develop vaccines to address the global health pandemic.

Dr. Glenn's presentation will be followed by a live Q&A discussion. Webinar details are as follows:

Topic: Recombinant Nanoparticle COVID-19 Vaccine: Platform Technology for Emerging Infectious Diseases (EID)  
Date and Time: Wednesday, May 13, 11:00 a.m. ET  
Moderator: Philip Krause, M.D., Deputy Director, OVRP, CBER, FDA

The webinar is free to attend. To register, please click [here](#).

### About NVX-CoV2373

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX-CoV2373 demonstrated efficient binding with receptors targeted by the virus, a critical aspect for effective vaccine protection. A Phase 1 clinical trial of NVX-CoV2373 will initiate in May 2020 with preliminary immunogenicity and safety results expected in July 2020. The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded an initial funding of \$4 million to support Novavax' NVX-CoV2373 efforts, with additional funding discussions ongoing.

### About Novavax

Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that addresses urgent global health needs through the discovery, development, and commercialization of innovative vaccines. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant nanoparticle vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles to address urgent global health needs.

For more information, visit [www.novavax.com](http://www.novavax.com) and connect with us on [Twitter](#) and [LinkedIn](#).

### Contacts:

Investors  
Erika Trahan  
[ir@novavax.com](mailto:ir@novavax.com)  
240-268-2022

Westwicke  
John Woolford  
[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)  
443-213-0506

Media  
Brandzone/KOGS Communication  
Edna Kaplan  
[kaplan@kogspr.com](mailto:kaplan@kogspr.com)  
617-974-8659

---

<https://ir.novavax.com/2020-05-11-Novavax-to-Present-COVID-19-Vaccine-Candidate-Progress-in-World-Vaccine-Congress-Webinar-Series>

